Enanta Pharmaceuticals Files Q3 2024 10-Q

TL;DR

Enanta Pharma's Q3 2024 10-Q is in. Check financials for latest updates.

AI Summary

Enanta Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company's fiscal year ends on September 30th. Key financial data and operational details for the third quarter are presented in this filing.

Why It Matters

This filing provides investors and analysts with the latest financial health and operational updates for Enanta Pharmaceuticals, crucial for understanding the company's trajectory in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Enanta faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• Q3 --09-30 2024 — Fiscal Quarter End (Reporting period for this 10-Q filing.)
• 0930 — Fiscal Year End (Enanta's annual fiscal year concludes on this date.)

Key Players & Entities

• ENANTA PHARMACEUTICALS INC (company) — Filer
• 20240630 (date) — Period of Report
• 0000950170-24-092714 (accession_number) — Filing Identifier
• 500 ARSENAL STREET (address) — Business and Mail Address
• WATERTOWN (city) — Business and Mail City
• MA (state) — Business and Mail State
• 02472 (zip_code) — Business and Mail Zip Code
• 617 607 0800 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA NASDAQ Indicate by

Filing Documents

• enta-20240630.htm (10-Q) — 1697KB
• enta-ex31_1.htm (EX-31.1) — 11KB
• enta-ex31_2.htm (EX-31.2) — 11KB
• enta-ex32_1.htm (EX-32.1) — 10KB
• img216962810_0.jpg (GRAPHIC) — 630KB
• 0000950170-24-092714.txt ( ) — 8367KB
• enta-20240630.xsd (EX-101.SCH) — 964KB
• enta-20240630_htm.xml (XML) — 1282KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 5. Other Information 28 Item 6. Exhibits 30

Signatures

Signatures 31 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "will" or the negative of these terms or other similar expressions. We caution you that the foregoing list may not encompass all of the forward-looking statements made in this Quarterly Report. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, our subsequently filed Quarterly Reports on Form 10-Q and as updated in Item 1A herein. 2 PAR T I—UNAUDITED FINANCIAL INFORMATION IT EM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ENANTA PHARMACEUTICALS, INC. CONDENSED CONS OLIDATED BALANCE SHEETS (unaudited) (in thousands, except per share data) June 30, September 30, 2024 2023 Assets Current assets: Cash and cash equivalents $ 35,775 $ 85,388 Short-term marketable securities 194,310 28

View Full Filing

View this 10-Q filing on SEC EDGAR